AbbVie Inc.
ABBV
$189.83
$2.361.26%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.45% | 3.71% | 0.72% | -1.83% | -4.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.45% | 3.71% | 0.72% | -1.83% | -4.12% |
| Cost of Revenue | -0.06% | 0.85% | -0.16% | -2.89% | -2.50% |
| Gross Profit | 7.91% | 4.99% | 1.09% | -1.35% | -4.83% |
| SG&A Expenses | 2.86% | 2.67% | 11.81% | 6.74% | 5.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 30.00% | 193.89% | 193.89% | 100.00% |
| Total Operating Expenses | 4.19% | 4.32% | 7.40% | 3.59% | 2.32% |
| Operating Income | 8.13% | 2.46% | -11.70% | -11.77% | -15.47% |
| Income Before Tax | -51.90% | -40.54% | -10.07% | -32.38% | -16.55% |
| Income Tax Expenses | -138.07% | -141.39% | 39.27% | -2.39% | 6.71% |
| Earnings from Continuing Operations | -30.00% | -12.05% | -21.29% | -38.45% | -20.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 27.27% | 20.00% | -57.14% | -57.14% | -37.50% |
| Net Income | -30.00% | -12.03% | -21.37% | -38.53% | -20.99% |
| EBIT | 8.13% | 2.46% | -11.70% | -11.77% | -15.47% |
| EBITDA | 4.30% | 0.46% | -9.53% | -8.97% | -10.57% |
| EPS Basic | -30.18% | -12.09% | -21.38% | -38.53% | -20.80% |
| Normalized Basic EPS | 5.99% | 1.17% | -12.37% | -11.85% | -14.73% |
| EPS Diluted | -30.25% | -12.11% | -21.38% | -38.41% | -20.51% |
| Normalized Diluted EPS | 6.03% | 1.24% | -12.33% | -11.81% | -14.69% |
| Average Basic Shares Outstanding | -0.01% | -0.01% | -0.06% | -0.14% | -0.20% |
| Average Diluted Shares Outstanding | -0.04% | -0.07% | -0.11% | -0.20% | -0.27% |
| Dividend Per Share | 5.28% | 5.01% | 4.73% | 4.79% | 4.84% |
| Payout Ratio | 0.50% | 0.19% | 0.33% | 0.70% | 0.32% |